EMERGING CLINICAL AND PRE-CLINICAL APPROACHES TO ONCOLYTICS

SUNDAY, MAY 15, 2022
All times listed below ET

Co-chairs: Balveen Kaur, PhD and John Goldberg, MD

Description
Oncolytic virus therapy has the potential to become a new arm of anti-cancer treatment, potentially augmenting existing immunotherapy approaches such as PD-1 inhibition and replacing others, such as chemotherapy, as combination partners for immunotherapy. In this workshop, the key leaders in the development of oncolytic virus therapy will present new approaches both in the lab and in the clinic in the development of oncolytic virus therapy.
EMERGING CLINICAL AND PRE-CLINICAL APPROACHES TO ONCOLYTICS

Schedule
All times listed below ET

8:00–8:25 AM
Progress and approval of G47delta
Tomoki Todo, PhD, Institute of Medical Science, University of Tokyo

8:25–8:50 AM
Development of Synthetic RNA Viral Immunotherapy
Lorena Lerner, PhD, Oncorus

8:50–9:15 AM
Drug Modulation of the Myeloid Tumor Microenvironment to Enable Oncolytic HSV Immunotherapy
Timothy Cripe, MD, PhD, Nationwide Children’s Hospital

9:15–9:40 AM
Combinations of Early Trials
Howard Kaufman, MD, Harvard University

9:40–9:55 AM
Break

9:55–10:20 AM
A Therapy Going Viral: Armed-oncolytic Adenoviruses for the Treatment of Solid Tumors
Candelaria Gomez-Manzano, MD, MD Anderson Cancer Center
EMERGING CLINICAL AND PRE-CLINICAL APPROACHES TO ONCOLYTICS

10:20–10:45 AM
An Oncolytic Herpes Virus Armed with a Full-length Anti-CD47 Antibody to Target “Don’t Eat Me” Signal and Fc Receptor-Mediated Antitumor Immunity
Jianhan Yu, PhD, City of Hope National Medical Center

10:45–11:10 AM
Bacterial Antigens Harnessed for Virotherapy
Evanthia Galanis, MD, DSc, Mayo Clinic

11:10–11:35 AM
Update in Clinical Trials of Oncolytic HSV for Brain Tumors
James Markert, MD, MPH, University of Alabama at Birmingham